ArticleAntibodies (Basel, Switzerland)2026
SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV.
Sharon L Walmsley, Leif Erik Lovblom, Bryan Boyachuk, Curtis Cooper, Valérie Martel-Laferrière, Mona Loutfy, Marie-Louise Vachon, Shariq Haider, Pamela Aldebes, Karen Colwill and 3 more
Abstract read
In one paragraphArticle in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Sharon L WalmsleyDivision of Infectious Diseases, University Health Network, Toronto, ON M5G 2C4, Canada.ORCID 0000-0002-3959-5692 Leif Erik LovblomBiostatistical Research Unit, University Health Network, Toronto, ON M5G 2C4, Canada.ORCID 0000-0002-6774-8924 Bryan BoyachukDivision of Infectious Diseases, University Health Network, Toronto, ON M5G 2C4, Canada.
Curtis CooperOttawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Valérie Martel-LaferrièreCHUM-Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X 0A9, Canada.ORCID 0000-0001-7973-8582 Mona LoutfyWomen's College Hospital Research Institute, Toronto, ON M5G 1N8, Canada.
Marie-Louise VachonFaculty of Medicine, CHU de Québec-Université Laval, Quebec, QC G1V 4G2, Canada.
Shariq HaiderMcMaster University Hospital, Hamilton, ON L8S 4K1, Canada.
Pamela AldebesThe Research Institute of the McGill University Health Centre, Montreal, QC H3A 1A1, Canada.
Karen ColwillLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.ORCID 0000-0002-8979-1659 Anne Claude GingrasLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
Freda QiLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
Marina B KleinDivision of Infectious Diseases, McGill University Health Center, Montreal, QC H4A 3J1, Canada.
Funding
Merck Canada ISS60289
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
antibody responsesCOVID-19hepatitis CHIVSARS-CoV-2vaccines
Identifiers
PMID42041389
PMCPMC13113170
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390